Cargando…

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study

We aimed to explore the efficacy and safety of once‐weekly trelagliptin 100 mg as an add‐on therapy to insulin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control. Patients with haemoglobin A1c (HbA1c) 7.5% to 10.0% who were receiving 8 to 40 units of insulin per day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaku, Kohei, Kuroda, Shingo, Ishida, Kazuyuki, Umeda, Yuusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175153/ https://www.ncbi.nlm.nih.gov/pubmed/29862617 http://dx.doi.org/10.1111/dom.13397

Ejemplares similares

Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end‐stage renal disease: Results from a randomized, phase 3 study
por: Kaku, Kohei, et al.
Publicado: (2019)

Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Randomized, double‐blind, phase III study to evaluate the efficacy and safety of once‐daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2017)

Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes
por: Tosaki, Takahiro, et al.
Publicado: (2017)

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
por: Kaku, Kohei, et al.
Publicado: (2017)

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan
por: Kaku, Kohei, et al.
Publicado: (2015)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial
por: Kaneko, Shizuka, et al.
Publicado: (2018)

Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin
por: Zaghary, Wafaa A., et al.
Publicado: (2017)

Different Spectrophotometric Methods for Simultaneous Determination of Trelagliptin and Its Acid Degradation Product
por: Mowaka, Shereen, et al.
Publicado: (2018)

Investigation of Pharmacokinetic Parameters of Trelagliptin in Egyptian Volunteers Using Sensitive LC-MS/MS: A Comparative Study with a Japanese Population
por: Mowaka, Shereen, et al.
Publicado: (2021)

Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol
por: Ishii, Hitoshi, et al.
Publicado: (2017)

Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study
por: Harashima, Shin‐ichi, et al.
Publicado: (2018)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials
por: Komatsu, Mitsuhisa, et al.
Publicado: (2021)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
por: Nakaigawa, Noboru, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
por: Tobe, Kazuyuki, et al.
Publicado: (2017)

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2012)

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes
por: Nishimura, Rimei, et al.
Publicado: (2019)

28‐week, randomized, multicenter, open‐label, parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2010)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)
por: Terauchi, Yasuo, et al.
Publicado: (2018)

Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor
por: Ishii, Hitoshi, et al.
Publicado: (2019)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
por: Kaku, Kohei, et al.
Publicado: (2014)

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial
por: Iwamoto, Yasuhiko, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
por: Kadowaki, Takashi, et al.
Publicado: (2021)

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Efficacy and Safety Results of the Afatinib Expanded Access Program
por: Kim, Edward S., et al.
Publicado: (2017)

Verification of Safety and Efficacy of Sleeve Gastrectomy Based on National Registry by Japanese Society for Treatment of Obesity
por: Okazumi, Shinichi, et al.
Publicado: (2023)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis
por: Shao, Haiyu, et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
por: Onishi, Yukiko, et al.
Publicado: (2020)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
por: McInnes, Iain B., et al.
Publicado: (2022)

Efficacy and safety of once‐daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26‐week, treat‐to‐target trial
por: Kadowaki, Takashi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h5oaak4thql8s32qbnvgnoltss